Sutura, Inc.
OTC Bulletin Board : SUTU

Sutura, Inc.

May 25, 2006 16:30 ET

Sutura Expands its Distribution Network at Top European Cardiovascular Conference

PARIS, FRANCE--(CCNMatthews - May 25, 2006) -

- SUPERSTITCH AND KWIKNOT SUTURING DEVICES SHOWCASED AT EUROPCR 2006 -

Sutura®, Inc. ("Sutura") (OTCBB:SUTU) a California-based medical device company, announced today that the Company recently completed successful participation at EuroPCR 2006. EuroPCR (www.europcronline.com) is the largest annual gathering of interventional cardiologists, radiologists, and vascular surgeons in Europe.

Sutura attended EuroPCR 2006 to showcase its 'As Simple As 1-2-3' SuperStitch and its new KwiKnot vascular suturing device to the European marketplace. The SuperStitch line of products is used in connection with cardiovascular and vascular procedures that require closure of the incision site following procedures such as angioplasty, cardiac catherization, vascular interventions and coronary arterial stenting.

"We were very excited to showcase the SuperStitch and KwiKnot to our current and future European customers," said Tom Lindsey, Vice President of Marketing and Sales. "Response to the innovative SuperStitch was very positive and we expect this to translate into sales growth in the future as more centers are getting trained in the use of the product."

Egbert Ratering, Sutura's CFO and Executive Vice President of European operations added, "At the meeting we concluded several new distribution agreements that will expand our sales to the UK, Netherlands, Belgium, Greece, Scandinavia, Turkey, and several smaller countries. Based on the positive feedback received from the distribution partners that already have started selling the SuperStitch we anticipate a ramp up of sales in the second half of this fiscal year."

About Sutura, Inc.

Sutura®, Inc. (www.sutura.us) is a medical device company that has developed a line of innovative, minimally invasive, vascular suturing devices to suture the puncture created in arteries during open surgery and catheter-based procedures. The Company's line of SuperStitch medical devices provide sutured closure of the arteriotomy site utilizing the existing catheter sheath introducer or cannula during fluoroscopically guided procedures and directly through the open arteriotomy during open surgical procedures.

Within the United States the 8F & 6F SuperStitch devices are available for use in performing vascular stitching in general surgery, including endoscopic procedures. It is not intended for blind closure of an arteriotomy site. The SuperStitch 8F & 6F is approved in the European Union and CE marked with the indication for use as follows: The SuperStitch is indicated for use in performing vascular stitching in general surgery, including endoscopic procedures. In the EU there is no requirement for the use of fluoroscopic guidance. Sutura's headquarters are in Fountain Valley, California. "Sutura®" and "SuperStitch®" are registered trademarks of Sutura, Inc.

Forward-Looking Information Is Subject to Risk and Uncertainty

Certain statements in this press release may contain projections or "forward-looking" information (as defined in the Private Securities Litigation Reform Act of 1995) that involve risk and uncertainty. The words "aim", "plan", "likely", "believe", "expect", "anticipate", "intend", "estimate", "will", "should", "could", "may", "appears", and other expressions that indicate future events and trends identify forward-looking statements. These statements are not guaranties of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what we express or forecast in these forward-looking statements. As a result, these statements speak only as of the date they were made and we undertake no obligation to publicly update or revise any forward-looking statements. Our actual results and future trends may differ materially from our forward-looking statements depending on a variety of factors including the acceptance of the SuperStitch® devices by medical providers and the marketplace in general and the success of the proposed sales and marketing plan, the continued growth of the vessel closure marketplace, the company's ability to obtain needed equity or debt financing in the future, and the company's ability to continue to expand and protect its technology patents.

Contact Information

  • Sutura, Inc.
    Barry Forward
    Corporate Communications
    (866) 676-8386
    www.sutura.us